Neuralstem, Inc. (NASDAQ:CUR) CFO Jones Jonathan Brian Lloyd bought 5,455 shares of Neuralstem stock in a transaction dated Friday, March 24th. The shares were acquired at an average price of $5.50 per share, with a total value of $30,002.50. Following the completion of the purchase, the chief financial officer now directly owns 7,859 shares in the company, valued at approximately $43,224.50. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.
Neuralstem, Inc. (NASDAQ:CUR) traded up 0.18% during mid-day trading on Monday, reaching $5.51. The company had a trading volume of 78,261 shares. The company’s market capitalization is $60.86 million. The stock has a 50-day moving average of $4.41 and a 200 day moving average of $1.82. Neuralstem, Inc. has a 12-month low of $2.47 and a 12-month high of $10.61.
ILLEGAL ACTIVITY WARNING: This article was originally published by Mideast Time and is the property of of Mideast Time. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.mideasttime.com/jones-jonathan-brian-lloyd-acquires-5455-shares-of-neuralstem-inc-cur-stock/1589640.html.
Separately, S&P Equity Research reduced their price target on Neuralstem from $3.69 to $3.18 in a research note on Thursday, February 16th.
Neuralstem Company Profile
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.